Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US38341P1021
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00MVWLLM2
GOSS
Gossamer Bio Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Gossamer Bio Inc
ISIN
US38341P1021
TICKER
GOSS
MIC
XNAS
REUTERS
GOSS.OQ
BLOOMBERG
GOSS US
Mi., 10.09.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 29.08.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 16.06.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced enrollment completion for the ongoing, global r...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 06.06.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 15.05.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter end...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 12.05.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 fina...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present a poster at the America...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 08.04.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 13.03.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter an...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 07.03.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 07.02.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board o...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 03.02.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented one oral presentation and three posters related to seraluti...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 28.01.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced one oral and three poster presentations related to se...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 07.01.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board o...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 11.11.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board o...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 07.11.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended Sep...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 07.10.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board o...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 26.08.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced two oral presentations and a poster presentation with...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 12.08.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended Ju...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 03.02.2023       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - February 2, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Gossamer and c...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Sa., 31.12.2022       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - December 30, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Gossamer and...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Sa., 17.12.2022       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - December 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Gossamer and...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 02.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 2, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 02.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 2, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" or "Offering"); and/or...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 02.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 2, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Far...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 02.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 2, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. ("Gossamer") (NASDAQ: GOSS) The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 02.06.2020       Gossamer Bio
US38341P1021

Los Angeles, California--(Newsfile Corp. - June 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 01.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 1, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" or "Offering"); and/or...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 01.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 1, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS)("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 01.06.2020       Gossamer Bio
US38341P1021

Los Angeles, California--(Newsfile Corp. - June 1, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 01.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 1, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" or "Offering"); and/or...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
So., 31.05.2020       Gossamer Bio
US38341P1021

Los Angeles, California--(Newsfile Corp. - May 31, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 pro...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 29.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 29, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 29.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 29, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 29.05.2020       Gossamer Bio
US38341P1021

Los Angeles, California--(Newsfile Corp. - May 29, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 28, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" or "Offering"); and/or...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 28, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 28, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Compan...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2020       Gossamer Bio
US38341P1021

Los Angeles, California--(Newsfile Corp. - May 28, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 prom...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 27.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 27, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 27.05.2020       Gossamer Bio
US38341P1021

Los Angeles, California--(Newsfile Corp. - May 27, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 27.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 27, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 26.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 26, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 22.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 22, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 22.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 21, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 20.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 20, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 19.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 19, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 18.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 18, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faru...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2020       Gossamer Bio
US38341P1021

San Diego, California--(Newsfile Corp. - April 20, 2020) -  The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: GOSS shares.Investors, who purchased shares of Gossamer Bio, Inc. (NASDAQ: GOSS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.co...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink